Effects of diazoxide in multiple sclerosis
A randomized, double-blind phase 2 clinical trial
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received March 17, 2015
- Accepted in final form July 15, 2015
- First Published September 10, 2015.
Author Disclosures
- Pablo Villoslada, MD,
- Alex Rovira, MD,
- Xavier Montalban, MD,
- Rafael Arroyo, MD,
- Friedemann Paul, MD,
- Virginia Meca-Lallana, MD,
- Cristina Ramo, MD,
- Oscar Fernandez, MD,
- Albert Saiz, MD,
- Antonio Garcia-Merino, MD,
- Lluís Ramió-Torrentà, MD,
- Bonaventura Casanova, MD,
- Celia Oreja-Guevara, MD,
- Delicias Muñoz, MD,
- Jose Enrique Martinez-Rodriguez, MD,
- Eckart Lensch, MD,
- Jose Maria Prieto, MD,
- Sven G. Meuth, MD, PhD,
- Xavier Nuñez, PhD,
- Clara Campás, PhD,
- Marco Pugliese, PhD;
- For the NeuroAdvan study
- Pablo Villoslada, MD,
Roche, Novartis, Neurotec Farma, Bionure Farma; Consultant: Novartis, Roche, TFS, Heidelberg Engineering, MedImmune, Digna Biotec, Neurotec Pharma
NONE
Novartis, Roche
PloSONE, Academic editor, 2011-- Neurology & Therapy, editorial board, 2014Curr There Op Neurol, editorial board 2014 Mult Scl & Demyel Dis, editorial board 2015
1. Methyltioadenosine for the treatment of MS 2. Agonistic neurotrophic compounds for the treatment of brain Diseases 3. Gene signature pattern as a biomarker for MS4. Algorithm for quantifying fractal dimension in brain MRI
NONE
NONE
NONE
NONE
NONE
NONE
unrestricted grants from Novartis, Roche and Genzyme
Instituto de Salud Carlos III, European Commission, National MS Society
NONE
Fundacion Maraton TV3
Bionure Pharma
NONE
NONE
NONE
NONE
NONE
- Alex Rovira, MD,
(1) Novartis, (2) Biogen, (3) Genzyme
NONE
(1) Bayer, (2) Teva Pharmaceutical Industries Ltd, (3) Genzyme, (4) Bracco, (5) Merck-Serono, (6) Biogen Idec, (7) OLEA
Editorial boards of: (1) Am J Neuroradiol. Editorial board member, 2008 at present; (2) Neuroradiology. Editorial board member, 2006 at present;
NONE
NONE
NONE
NONE
(1) Bayer, (2) Teva Pharmaceutical Industries Ltd, (3) Genzyme, (4) Bracco, (5) Merck-Serono, (6) Biogen Idec, (7) OLEA
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Xavier Montalban, MD,
(1) Novartis, (2) Teva Pharmaceutical, (3) Merck, (4) Biogen, (5) Bayer, (6) Almirall, (7) Actelion, (8) Genzyme, (9) Octapharma, (10) Receptos, (11) Roche, (12) Sanofi, (13) Trophos
NONE
Travel to scientific meetings: (1) Novartis, (2) Teva Pharmaceutical, (3) Merck, (4) Biogen, (5) Bayer, (6) Almirall, (7) Actelion, (8) Genzyme, (9) Octapharma, (10) Receptos, (11) Roche, (12) Sanofi, (13) Trophos
Member of editorial boards: (1) Multiple Sclerosis, (2) Journal of Neurology, (3) The International MS Journal, (4) Revista Neurologia, (5) Therapeutic Advances in Neurological Disorders
NONE
NONE
NONE
(1) Novartis, (2) Teva Pharmaceutical, (3) Merck, (4) Biogen, (5) Bayer, (6) Almirall, (7) Actelion, (8) Genzyme, (9) Octapharma, (10) Receptos, (11) Roche, (12) Sanofi, (13) Trophos
NONE
NONE
NONE
NONE
NONE
NONE
Vice President, Multiple Sclerosis Foundation of Barcelona (FEM)
NONE
NONE
NONE
NONE
NONE
NONE
- Rafael Arroyo, MD,
Teva, Biogen, Novartis, Merck-Serono, Roche, Bayer, Genzyme, Sanofi, Almirall
NONE
Teva, Biogen, Novartis, Merck-Serono, Roche, Bayer, Genzyme, Sanofi, Almirall: speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Friedemann Paul, MD,
Novartis OCTIMS study steering committee MedImmune steering committee
NONE
speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono
Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation
NONE
NONE
NONE
consultancies for SanofiGenzyme, BiogenIdec, MedImmune
NONE
NONE
NONE
Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono
German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis)
NONE
Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA
NONE
NONE
NONE
NONE
NONE
NONE
- Virginia Meca-Lallana, MD,
Roche
NONE
Biogen Idec, Novartis, Merk, TEVA
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Cristina Ramo, MD,
NONE
NONE
Travel funded by a commercial entity to attend conferences Honoraria for speaking engagements
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Biogen, Genzyme, Novartis, Almirall
Instituto de Salud Carlos III. Spain Fondo de Investigaciones Sanitarias (FIS). Spain
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Oscar Fernandez, MD,
has received honoraria as consultant in advisory boards, and as chairmen or lecturer in meetings, and has also participated or participates at present in clinical trials and other research projects promoted by Biogen-Idec, Bayer-Schering; Merck-Serono, Teva, Novartis, Actelion, Almirall and Allergan.
NONE
has received honoraria as consultant in advisory boards, and as chairmen or lecturer in meetings, and has also participated or participates at present in clinical trials and other research projects promoted by Biogen-Idec, Bayer-Schering; Merck-Serono, Teva, Novartis, Actelion, Almirall and Allergan.
Revista de Multiple Sclerosis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
has received honoraria as consultant in advisory boards, and as chairmen or lecturer in meetings, and has also participated or participates at present in clinical trials and other research projects promoted by Biogen-Idec, Bayer-Schering; Merck-Serono, Teva, Novartis, Actelion, Almirall and Allergan.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Albert Saiz, MD,
(1) Biogen Idec, (2) Merck-Serono
NONE
(1) Bayer-Schering, (2) Merck-Serono, (3) Biogen Idec, (4) Sanofi-Aventis, (5) Teva Pharmaceutical Industries, (6) Novartis
NONE
NONE
NONE
NONE
(1) Bayer-Schering, (2) Merck-Serono, (3) Biogen-Idec, (4) Sanofi-Aventis, (5) Teva Pharmaceutical Industries, (6) Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Antonio Garcia-Merino, MD,
Biogen, Idec, Novartis, Roche, Genzyme, Merck
NONE
Biogen, Idec, Novartis, Almirall, Genzyme, Roche, Merck
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research grants from Novartis and Biogen Idec
Research grant from FIS years 2012-15
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lluís Ramió-Torrentà, MD,
(1) Biogen, (2) Roche, (3) Novartis, (4) TEVA
(1) Biogen, congresses, (2) Roche, congresses, (3) Novartis, congresses, (4) TEVA, congresses, (5) Bayer-Schering, congresses, (6) Merck-Serono, congresses, (7) Genzyme, congresses
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bonaventura Casanova, MD,
Biogen-Idec, Cenzyme, TEVA, Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Celia Oreja-Guevara, MD,
Genzyme (1)
NONE
(1) Speaker honoraria by Biogen, Novartis, Teva, Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Delicias Muñoz, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jose Enrique Martinez-Rodriguez, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Consulting services to Roche and Bayer.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eckart Lensch, MD,
NONE
NONE
Bayer GmbH, speaker honorarium Merck Serono GmbH, speaker honorarium
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jose Maria Prieto, MD,
Biogen, Novartis, Bayer, Merck-SERONO, Teva, Genzyme and Almirall
NONE
Biogen, Novartis, Bayer, Merck-SERONO, Teva, Genzyme and Almirall
NONE
NONE
NONE
NONE
Biogen, Novartis, Bayer, Merck-SERONO, Teva, Genzyme and Almirall
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sven G. Meuth, MD, PhD,
NONE
NONE
NONE
PLoS One
NONE
NONE
NONE
Sven G. Meuth (SGM) has received honoraria for lecturing and travel expenses for attending meetings and has received financial research support from Bayer, Bayer Schering, Biogen Idec, Genzyme, Merck Serono, MSD, Novartis, Novo Nordisk, Sanofi-Aventis and Teva.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Xavier Nuñez, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Clara Campás, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Advancell, Advanced In Vitro Cell Technologies, SA SME biomedicine company 2006 to 2014 Managing Director
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marco Pugliese, PhD;
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- For the NeuroAdvan study
- From the Institut d' Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)—Hospital Clinic (P.V., A.S.), Barcelona, Spain; Unitat de RM (Servei de Radiologia) (A.R., X.M.), Departamento de Neurología-Neuroinmunología, Centro de Esclerosis Múltiple de Cataluña (Cemcat), Hospital Vall d'Hebron, Barcelona, Spain; Hospital Clinico San Carlos (R.A., C.O.-G.), Madrid, Spain; NeuroCure Clinical Research Center and Department of Neurology (F.P.), Charité University Medicine Berlin, Berlin, Germany; Hospital de La Princesa (V.M.-L.), Madrid, Spain; Hospital Germans Trias i Pujol (C.R.), Badalona, Spain; Hospital Regional Universitario (IBIMA) (O.F.), Malaga, Spain; Hospital Puerta de Hierro (A.G.-M.), Madrid, Spain; Hospital Universitari Dr Josep Trueta (L.R.-T.), IDIBGI, Girona, Spain; Hospital La Fe (B.C.), Valencia, Spain; Hospital Xeral-Cies (D.M.), Vigo, Spain; Hospital del Mar (J.E.M.-R.), Barcelona, Spain; Deutsche Klinik für Diagnostik (E.L.), Wiesbaden, Germany; Hospital Universitario Santiago de Compostela (J.M.P.), Spain; Department of Neurology (S.G.M.), University of Munster, Germany; TrialFormSupport (X.N.), Barcelona, Spain; Advancell, Advanced In Vitro Cell Technologies, S.A (C.C.), Barcelona, Spain; and Neurotec Pharma S.L (M.P.), Barcelona, Spain.
- Correspondence to Dr. Villoslada: pvilloslada{at}clinic.ub.es
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Ann Yeh and Dr. Daniela Castillo Villagrán
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MSVolker Limmroth, Frederik Barkhof, Nuket Desem et al.Neurology, September 19, 2014 -
Articles
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapsesP. W. O’Connor, D. Li, M. S. Freedman et al.Neurology, March 27, 2006 -
Article
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFITKassandra L. Munger, Kathryn C. Fitzgerald, Mark S. Freedman et al.Neurology, October 09, 2015 -
Article
Oral contraceptives combined with interferon β in multiple sclerosisCarlo Pozzilli, Laura De Giglio, Valeria T. Barletta et al.Neurology - Neuroimmunology Neuroinflammation, June 18, 2015